| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.24 | 4e-06 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.12 | 5e-05 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0002 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.2 | 0.0002 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.2 | 0.0003 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0006 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0008 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.57 | 0.001 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.16 | 0.001 |